ES2095960T3 - Compuestos que tienen propiedades antihipertensivas y antiisquemicas. - Google Patents

Compuestos que tienen propiedades antihipertensivas y antiisquemicas.

Info

Publication number
ES2095960T3
ES2095960T3 ES91917927T ES91917927T ES2095960T3 ES 2095960 T3 ES2095960 T3 ES 2095960T3 ES 91917927 T ES91917927 T ES 91917927T ES 91917927 T ES91917927 T ES 91917927T ES 2095960 T3 ES2095960 T3 ES 2095960T3
Authority
ES
Spain
Prior art keywords
compounds
hypertensive
ischemical
properties
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91917927T
Other languages
English (en)
Inventor
Alfred P Spada
Cynthia A Fink
Michael R Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Rorer International Holdings Inc
Original Assignee
Rhone Poulenc Rorer International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer International Holdings Inc filed Critical Rhone Poulenc Rorer International Holdings Inc
Application granted granted Critical
Publication of ES2095960T3 publication Critical patent/ES2095960T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A DERIVADOS DE LA ADENOSINA Y A ANALOGOS DE LA MISMA QUE POSEEN ACTIVIDAD ANTAGONISTA PARA LA ADENOSINA Y SON UTILES COMO AGENTES ANTIHIPERTENSIVOS Y ANTIISQUEMICOS, ASI COMO A LAS COMPOSICIONES FARMACEUTICAS QUE INCLUYEN TALES COMPUESTOS, Y A SU USO EN EL TRATAMIENTO DE LA HIPERTENSION Y DE LA ISQUEMIA DE MIORCARDIO, Y A METODOS Y PRODUCTOS INTERMEDIOS USADOS EN LA PREPARACION DE TALES COMPUESTOS.
ES91917927T 1990-09-25 1991-09-25 Compuestos que tienen propiedades antihipertensivas y antiisquemicas. Expired - Lifetime ES2095960T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58788490A 1990-09-25 1990-09-25

Publications (1)

Publication Number Publication Date
ES2095960T3 true ES2095960T3 (es) 1997-03-01

Family

ID=24351576

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91917927T Expired - Lifetime ES2095960T3 (es) 1990-09-25 1991-09-25 Compuestos que tienen propiedades antihipertensivas y antiisquemicas.

Country Status (13)

Country Link
US (1) US5364862A (es)
EP (1) EP0550631B1 (es)
JP (1) JP2505085B2 (es)
AT (1) ATE147074T1 (es)
AU (1) AU654507B2 (es)
CA (1) CA2092305C (es)
DE (1) DE69123974T2 (es)
DK (1) DK0550631T3 (es)
ES (1) ES2095960T3 (es)
GR (1) GR3022207T3 (es)
MX (1) MX9203771A (es)
SG (1) SG80526A1 (es)
WO (1) WO1992005177A1 (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
AU654507B2 (en) * 1990-09-25 1994-11-10 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
FR2685918B1 (fr) * 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
DK155292D0 (da) * 1992-12-23 1992-12-23 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
US5683989A (en) * 1993-12-17 1997-11-04 Novo Nordisk A/S Treatment of ischemias by administration of 2,N6 -substituted adenosines
FR2714907B1 (fr) * 1994-01-07 1996-03-29 Union Pharma Scient Appl Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant.
WO1995018817A1 (fr) * 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
GB9414208D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5684159A (en) * 1995-05-30 1997-11-04 Rhone-Poulenc Rorer S.A. L-tartaric acid salt of a (1R) diastereomer of a 2-azadihydroxybicyclo 2.2.1!heptane compound and the preparation of 2-azabicyclo 2.2.1!heptane compounds
FR2734822B1 (fr) * 1995-05-30 1997-07-04 Rhone Poulenc Rorer Sa Nouveaux derives du 2-azabicyclo(2.2.1)heptane, leur preparation et leur application
US5670649A (en) * 1995-05-30 1997-09-23 Rhone-Poulenc Rorer S.A. Derivatives of 2-azabicyclo 2.2.1!heptane, their preparation and their application
ZA9756B (en) * 1996-01-16 1997-07-17 Warner Lambert Co Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines
US6376472B1 (en) 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US5747474A (en) * 1996-07-29 1998-05-05 Immune Modulation, Inc. Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides
WO1998011064A1 (en) * 1996-09-12 1998-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Stereospecific preparation of chiral 1-aryl- and 1-heteroaryl-2-substituted ethyl-2-amines
ES2242984T3 (es) * 1996-12-11 2005-11-16 Aventis Pharmaceuticals Inc. Preparacion de (1s-(1a,2b,3b,4a(s*)))-4-(7-((1-(3-cloro-2-tienil) metil)propil)amino)-3h-imidazo (4,5-b)piridin-3-il)-n-etil-2-3-dihidroxiciclopentancarboxamida.
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2305726A1 (en) 1997-10-07 1999-04-15 Regents Of The University Of California Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
JP3933870B2 (ja) 1998-06-23 2007-06-20 グラクソ グループ リミテッド ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
JP3619017B2 (ja) 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
KR20010087425A (ko) * 1998-12-21 2001-09-15 오흘러 로스 제이. Ｎ6-치환된 데아자-아데노신 유도체의 제조방법
PT1140933E (pt) 1998-12-31 2004-12-31 Aventis Pharma Inc Processo para preparar derivados n6-substituidos de desaza-adenosina
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6784165B1 (en) * 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
HU228783B1 (en) * 2001-07-26 2013-05-28 Greenearth Cleaning Dry cleaning apparatus and method capable of utilizing a siloxane solvent
NZ556354A (en) 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US7265111B2 (en) * 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
CA2513545A1 (en) * 2003-01-17 2004-08-05 Ajinomoto Co., Inc. Processes for production of nucleosides
WO2004100964A1 (en) * 2003-04-24 2004-11-25 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
US20050118262A1 (en) * 2003-09-17 2005-06-02 Jack Aurora Controlled release formulation
EP1574508A1 (de) * 2004-01-30 2005-09-14 Lonza AG Verfahren zur Herstellung von Acetalen und Ketalen von 3-Amino-5-(hydroxymethyl)-cyclopentan-1,2-diolen, sowie deren Derivaten und Salzen
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
MX2010007419A (es) * 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
EP2358720B1 (en) 2008-10-16 2016-03-02 The Regents of The University of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10301348B2 (en) * 2013-10-23 2019-05-28 Academia Sinica Compounds for use in prevention and treatment of neurodegenerative diseases and pain
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
EP3884026B1 (en) 2018-11-20 2024-06-26 Unilever Global Ip Limited Detergent composition
WO2022135365A1 (en) * 2020-12-22 2022-06-30 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Disubstituted cyclopentane kinase inhibitors
KR102308854B1 (ko) * 2021-02-26 2021-10-05 퓨쳐메디신 주식회사 카보사이클릭 뉴클레오사이드 유도체를 포함하는 코로나바이러스감염증-19 예방 및 치료용 약학적 조성물

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL128629C (es) * 1966-05-07
US3796700A (en) * 1970-06-30 1974-03-12 Takedo Chem Ind Ltd Adenosine derivatives and the production thereof
DE2059922A1 (de) * 1970-12-05 1972-06-15 Boehringer Mannheim Gmbh Neue N(6)-Aralkyl-adenosin-Derivate und Verfahren zur Herstellung derselben
DE2205002A1 (de) * 1972-02-03 1973-08-09 Merck Patent Gmbh Adenosinderivate
DE2136624A1 (de) * 1971-07-22 1973-02-08 Boehringer Mannheim Gmbh N (6)-substituierte adenosin-derivate und verfahren zur herstellung derselben
DE2139107A1 (de) * 1971-08-04 1973-02-15 Merck Patent Gmbh Heterocyclisch substituierte adenosinverbindungen
DE2151013C2 (de) * 1971-10-08 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von in N↑6↑-Stellung gegebenenfalls substituierten 6-Amino- und 2,6-Diaminopurinnucleosiden
US3914415A (en) * 1973-06-14 1975-10-21 Abbott Lab Adenosine-5{40 -carboxylic acid amides
US4167565A (en) * 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
JPS5921928A (ja) * 1982-07-28 1984-02-04 Haruo Kojima 給湯装置
JPS59219284A (ja) * 1983-05-27 1984-12-10 Toyo Jozo Co Ltd ３′−デオキシネプラノシンａおよびその製造法
US4501735A (en) * 1983-12-05 1985-02-26 Warner-Lambert Company N6-(1- and 2-benzocycloalkyl) adenosines
EP0300144A3 (en) * 1984-04-18 1989-09-27 Whitby Research Incorporated N-6 alkyl substituted adenosine derivatives as cardiac vasodilators
US4657898A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines and method of use
US4657897A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines for treating pain
US4593019A (en) * 1984-10-26 1986-06-03 Warner-Lambert Company N6 -tricyclic adenosines
US4683223A (en) * 1985-09-09 1987-07-28 Warner-Lambert Company N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4600707A (en) * 1985-01-25 1986-07-15 Warner-Lambert Company Benzothien-3-yl adenosine; benzothien-3-yl adenosine, S-oxide; and benzothien-3-yl, S,S-dioxide adenosine compounds
US4636493A (en) * 1985-01-25 1987-01-13 Warner-Lambert Company Benzothien-3-yl adenosine; benzothien-3-yl adenosine, S-oxide; and benzothien-3-yl, S,S-dioxide adenosine compounds
DE3529497A1 (de) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) * 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US4780452A (en) * 1986-09-08 1988-10-25 Burroughs Wellcome Co. F-substituted-3-β-D-ribofuranosyl-3H-imidazo[4,5-b]pyridines and pharmaceutical compositions thereof
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5063233A (en) * 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
US4843066A (en) * 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
HU198950B (en) * 1986-12-15 1989-12-28 Sandoz Ag Process for producing new furanuronic acid derivatives and pharmaceutical compositions comprising such compounds
EP0277917A3 (en) * 1987-02-04 1990-03-28 Ciba-Geigy Ag Certain adenosine 5'-carboxamide derivatives
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
CA1340361C (en) * 1987-04-24 1999-02-02 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US4977144A (en) * 1988-08-02 1990-12-11 Ciba-Geigy Corporation Imidazo[4,5-b]pyridine derivatives as cardiovascular agents
AU3820989A (en) * 1988-08-02 1990-02-08 Ciba-Geigy Ag 7-amino-3-beta-d-ribofuranosyl-3h-imidazo(4,5-b) pyridin-5-amine derivatives
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
GB8916480D0 (en) * 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
AU654507B2 (en) * 1990-09-25 1994-11-10 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties

Also Published As

Publication number Publication date
SG80526A1 (en) 2001-05-22
EP0550631A4 (en) 1994-08-10
EP0550631B1 (en) 1997-01-02
CA2092305C (en) 2003-02-11
EP0550631A1 (en) 1993-07-14
ATE147074T1 (de) 1997-01-15
AU654507B2 (en) 1994-11-10
MX9203771A (es) 1992-09-01
GR3022207T3 (en) 1997-04-30
HK1002031A1 (en) 1998-07-24
CA2092305A1 (en) 1992-03-26
JPH05508864A (ja) 1993-12-09
JP2505085B2 (ja) 1996-06-05
AU8726691A (en) 1992-04-15
DK0550631T3 (da) 1997-01-20
US5364862A (en) 1994-11-15
WO1992005177A1 (en) 1992-04-02
DE69123974T2 (de) 1997-05-07
DE69123974D1 (de) 1997-02-13

Similar Documents

Publication Publication Date Title
ES2095960T3 (es) Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
UA39168C2 (uk) Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
CA2188147A1 (en) Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
BG60698B2 (en) Pharmaceutical ACCEPTABLE SALTS
DK0725782T3 (da) A1-adenosin-receptor-agonister og antiagonister
ES2038613T3 (es) Procedimiento para preparar derivados de 4,5,6,7-tetrahidro-1h-imidazo(4,5-c)piridina y analogos de los mismos que tienen actividad antihipertensiva.
BG95705A (bg) Аналози на 1,3-оксатиолан нуклеозида
CY2607B2 (en) Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanylcyclyse agonists
DE69132141D1 (de) Neuroprotective indolone und verwandte derivate
CA2259538A1 (en) Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
DE69617273D1 (de) Heterocyclisch substituierte cyclopentanderivate.
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
IL155806A0 (en) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
MX9300603A (es) Derivados tiaciclicos de piperidinilo.
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
ES2191659T3 (es) Derivados heterociclicos substituidos utiles como inhibidores de la agregacion plaquetaria.
BG100069A (bg) Амидинови производни,съдържащи хетероциклични групи,получаване и приложението им
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
FR2685918B1 (fr) Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ATE113949T1 (de) Alpha-adrenergische rezeptorantagonisten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 550631

Country of ref document: ES